MarginsXMarginsX
Home › Markets › Health Care › NRIX

Nurix Therapeutics Inc. (NRIX)

NRIX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$14.73
-4.84% on the day
Market cap
$1.6B
Small cap
Revenue · 2025
$84.0M
+54.0% on 2024
Net income · 2025
-$264.5M
-314.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-11-30, https://www.sec.gov/Archives/edgar/data/1549595/000154959526000016/0001549595-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-11-30.

Profile

FieldValue
TickerNRIX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001549595
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$84.0M
Net income-$264.5M
Operating income-$285.7M
Net margin-314.9%
Operating margin-340.2%
Revenue growth+54.0%
Cash$247.0M
Total assets$688.1M
P/E (computed)Net income was not positive
P/S (computed)19.2×

Warning signs

Cash runway
Cash-flow positive
$720.2M cash at August 31, 2026
Share count, 1 year
+42.1%
2025-09-30 to 2026-09-30 · +125.2% over 3 years
Going-concern doubt
No
10-Q filed October 13, 2026
Insider net buying, 12 months
-$4.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Management considered whether there are conditions or events that raise substantial doubt about the Company's ability to continue as a going concern and evaluated the funds necessary to maintain operations."
10-Q 2026-10-13
Cash and burn$720.2M cash; operating cash flow $94.8M a quarter.Report 2026-08-31
Shares outstanding109,249,814 (2026-09-30); 76,883,436 a year earlier; 48,503,768 three years earlier.Cover page 2026-09-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-03-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-02-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-08-31
$673.1M$549.8M$615.6M$720.2MNo debt tags$701.9M10-Q 2026-10-13
Q2 2026
2026-05-31
$9.0M-$89.5M-$96.6M$67.7MNo debt tags$36.8M10-Q 2026-07-09
Q1 2026
2026-02-28
$6.3M-$87.2M-$71.9M$71.2MNo debt tags$71.8M10-Q 2026-04-08
Q4 2025
2025-11-30
$13.6M-$78.2M-$67.8M$247.0MNo debt tags$84.0M10-K 2026-01-28
Q3 2025
2025-08-31
$7.9M-$86.4M-$57.4M$78.4MNo debt tags$83.7M10-Q 2026-10-13
Q2 2025
2025-05-31
$44.1M-$43.5M-$63.2M$84.3MNo debt tags$88.4M10-Q 2026-07-09
Q1 2025
2025-02-28
$18.5M-$56.4M-$61.1M$75.9MNo debt tags$56.4M10-Q 2026-04-08
Q4 2024
2024-11-30
$13.3M-$58.5M-$48.8M$110.0MNo debt tags$54.5M10-K 2026-01-28

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-06
Latest annual report10-K2026-01-28
Latest quarterly / interim10-Q2026-10-13
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-03-27

Source: SEC EDGAR submissions feed, 567 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.2%
1 month-30.0%
3 months-43.1%
Year to date-18.4%
1 year+24.5%
From 52-week high-44.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ANIPANI Pharmaceuticals Inc.$70.89-0.77%$1.6B
RAREUltragenyx Pharmaceutical Inc.$15.90-1.12%$1.6B
SRPTSarepta Therapeutics Inc. Common Stock (DE)$15.13-5.85%$1.6B
KLRAKailera Therapeutics Inc.$12.57-5.28%$1.6B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
PGENPrecigen Inc.$4.30-5.29%$1.5B
QUREuniQure N.V.$21.88-8.11%$1.5B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier